In Vivo Investigation of Radiolabeled Bevacizumab in Healthy Rat Tissues

In this study, BevMab was conjugated with the bifunctional chelating agent [diethylenetriamine pentaacetic acid (DTPA)] and the product (BevMab-DTPA) was labeled with Tc using stannous chloride reducing method. The quality control studies of radiolabeled compound (Tc-BevMab-DTPA) were done with Thin Layer Radio Chromatography (TLRC) and High Performance Liquid Radio Chromatography (HPLRC) methods (% 95 ≤) to confirm the labeling efficiency. High radiochemical yield [98.07 % ± 2.17 (n = 13)] was obtained by TLRC method. Biodistribution studies of Tc labeled BevMab-DTPA was run on healthy female and male Albino Wistar rats. The distribution figures demonstrated that the radiolabeled compound was eliminated through the kidneys and accumulated in urinary bladder. The values of the BevMab-DTPA uptakes were similar in heart, blood, liver and spleen in both sexes.